Awiqli FlexTouch 700 Units 1x1ml Prefilled Pen Injection

Awiqli FlexTouch 700 Units 1x1ml  Prefilled Pen Injection contains Insulin Icodec, an ultra-long-acting basal insulin used to improve blood glucose control in patients with type 2 diabetes mellitus. It belongs to the group of medicines called long-acting insulin analogues.

Unlike conventional basal insulin injections that are administered once daily, Insulin Icodec is designed to provide prolonged blood glucose control through once-weekly subcutaneous administration.

To prevent interactions, inform your doctor about all other medications and supplements you are taking. Monitor your blood glucose regularly while using this medication. Seek immediate medical attention if you experience severe hypoglycemia or a serious allergic reaction. Pregnant or breastfeeding women should consult their healthcare provider before using this medication.

Brand Name: Awiqli FlexTouch

Composition: Insulin Icodec 700 Units/mL

Mechanism of Action:

Insulin Icodec is an ultra-long-acting insulin analogue that works similarly to naturally produced human insulin. It binds to insulin receptors on muscle and fat cells, promoting glucose uptake and utilization. It also inhibits glucose production by the liver, thereby helping to reduce blood glucose levels.

Insulin Icodec has been structurally modified to enable reversible binding to albumin in the bloodstream. This allows the insulin to remain in circulation for an extended period and provides a prolonged glucose-lowering effect.

Due to its ultra-long duration of action, Insulin Icodec is administered once weekly to provide continuous basal insulin coverage and help maintain stable blood glucose levels.

Uses:

· Type 2 Diabetes Mellitus

· Improvement of blood glucose control in patients with type 2 diabetes, along with diet and exercise.

Dosage and Administration:

Awiqli FlexTouch is administered as a subcutaneous injection once weekly, preferably on the same day each week.

The dosage is individualized according to the patient's blood glucose levels, previous insulin treatment, metabolic requirements and treatment goals.

It is administered subcutaneously into the abdomen, thigh or upper arm. Injection sites should be rotated regularly to reduce the risk of injection-site complications.

The 700 Units/mL prefilled pen contains 700 units of Insulin Icodec in 1 mL. The pen delivers doses in increments of 10 units, up to a maximum of 700 units per injection.

Patients switching from other insulin treatments must follow a specific dose-conversion and monitoring schedule under medical supervision.

Side Effects:

· Hypoglycemia

· Weight gain

· Injection-site reactions

· Redness or swelling at the injection site

· Itching

· Skin rash

· swelling

· Allergic reactions

· Hypersensitivity reactions

· Hypokalemia

Contraindications/Warnings:

Awiqli FlexTouch is contraindicated in patients experiencing an episode of hypoglycemia and in patients with known hypersensitivity to Insulin Icodec or any of its ingredients.

Severe hypoglycemia can occur due to excessive insulin dosage, missed meals, increased physical activity or changes in other antidiabetic medications. Severe or prolonged hypoglycemia may require immediate medical attention.

Do not share the FlexTouch pen or needles with another person, even if the needle is changed. Never transfer insulin from the pen into a syringe, as this may result in serious dosing errors and potentially life-threatening hypoglycemia.

Do not administer intravenously, intramuscularly or through an insulin infusion pump. Do not dilute or mix Awiqli with other insulin preparations.

Patients taking thiazolidinediones together with insulin should be monitored for fluid retention and symptoms of heart failure.

Safety Advice:

Liver

Patients with liver impairment should use Awiqli with caution. Changes in liver function may affect insulin requirements and blood glucose control. Regular glucose monitoring and individualized dosage adjustments may be necessary. Kindly consult your healthcare provider.\

Kidney

Patients with kidney impairment should use Awiqli under medical supervision. Changes in kidney function may increase the risk of hypoglycemia. Regular blood glucose monitoring and appropriate dosage adjustments are recommended. Kindly consult your healthcare provider.

Pregnancy

There is limited clinical information regarding the use of Insulin Icodec during pregnancy. Maintaining appropriate blood glucose levels is important during pregnancy. Pregnant women or those planning pregnancy should consult their healthcare provider to evaluate the benefits and potential risks before using this medication.

Lungs

There is limited specific information regarding the use of Awiqli in patients with lung diseases. Patients with respiratory conditions should consult their healthcare provider before using this medication.

Breast Feeding

There is limited information regarding the presence of Insulin Icodec in human breast milk and its effects on breastfed infants. Breastfeeding women should consult their healthcare provider to evaluate the benefits and potential risks before using this medication.

Alcohol

Alcohol may affect blood glucose levels and increase the risk of hypoglycemia in patients receiving insulin therapy. Avoid excessive alcohol consumption and consult your healthcare provider regarding alcohol use while taking Awiqli.

Storage:

· Store unopened Awiqli FlexTouch pens in a refrigerator at 2°C to 8°C.

· Protect the pen from direct heat and sunlight.

· After first use, the pen can be stored refrigerated at 2°C to 8°C or at room temperature below   30°C for up to 12 weeks, subject to the approved product leaflet.

How to Use This Medication?

Use Awiqli FlexTouch exactly as prescribed by your healthcare provider.

· Administer the injection subcutaneously once weekly on the same day each week.

· Check the product label before every injection to ensure you are using the correct insulin.

· Inspect the solution before administration. It should appear clear and colourless.

· Use a new disposable needle for every injection.

· Select the prescribed dose using the FlexTouch pen.

· Inject into the abdomen, thigh or upper arm and rotate injection sites regularly.

References:

1. European Medicines Agency (EMA). Awiqli (Insulin Icodec): European Public Assessment Report and Product Information.
2. Novo Nordisk. Awiqli (Insulin Icodec) Prescribing Information.
3. U.S. Food and Drug Administration (FDA). Awiqli (Insulin Icodec-abae) Full Prescribing Information, 2026.
4. DailyMed. Awiqli – Insulin Icodec-abae Injection: Drug Information and Prescribing Information.

Disclaimer:

The main goal of Apothecare Specialities Pvt Ltd is to make sure that the information it provides to customers is correct, reliable, and reviewed by specialists. This website's contents and information are strictly for informational purposes. They are not meant to be used in place of expert medical advice, diagnosis, or care. Please consult your physician for guidance and ask any questions you may have about any condition or medication. If you read anything on Apothecare Specialities Pvt Ltd, do not discount or delay obtaining competent medical advice. Our goal is to enhance the doctor-patient relationship, not to take its place.

Marketer Details

Name: Novo Nordisk India Pvt Ltd
Address: Novo Nordisk India Private Limited, Nxt Tower-2, Floor 1 & 2, Embassy Manyata Business park, Nagavara Village, Kasaba Hobli, Bangalore-560045, India.
Country of Origin: Denmark